Vice Chair, Clinical Research, Department of Hematology/Oncology
Fox Chase Cancer Center
Dr. Olszanski, Vice Chair of Clinical Research inthe Department of Medical Hematology and Oncology at Fox Chase Cancer Center, is the Director of the Early Clinical Drug Development Phase I Program and co-director of the Cutaneous Oncology Program. The Phase I program boasts a continual supply of highly relevant phase I trials across disease sites and for specific genomic alterations. At any given time, up to 35 Phase I trials are available and result in approximately 200 patient accruals/year. Dr. Olszanski completed his hematology and oncology fellowship, and clinical pharmacology fellowship at Dartmouth-Hitchcock Medical Center. He is board certified in internal medicine, medical oncology, and clinical pharmacology. As a Director in Early Clinical Development at Pfizer, Dr. Olszanski gained pharmaceutical experience in translational work, early and late-stage clinical drug development. Dr. Olszanski focuses on the treatment of lung cancer and cutaneous malignancies, with a focus on melanoma. He sits on the NCCN Melanoma panel and the Management of Immunotherapy-Related Toxicities panel, providing expert input into the NCCN guidelines development. Dr. Olszanski serves as a mentor to numerous oncology fellows, internal medicine residents, and colleagues. In addition to attracting a large number of sponsored Phase I trials, he has written, developed, and oversees (or serves as a sub-investigator on) many investigator-initiated trials. To date, at FCCC, Dr. Olszanski has served as the principal investigator on over 80 trials.
